Trial in progress: A phase I study of AMG 199, a half-life extended   bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in   patients with gastric and gastroesophageal junction (G/GEJ) cancer.

Document type:: Meeting Abstract
Author(s):: Chao, Joseph; Buxo, Elvira; Cervantes, Andres; Dayyani, Farshid; Rocha Lima, Caio Max Sao Pedro; Greil, Richard; Van Laarhoven, Hanneke W. M.; Lorenzen, Sylvie; Heinemann, Volker; Kischel, Roman; Shitara, Kohei; Lordick, Florian
Title:: Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GEJ) cancer.
Journal title abbreviation:: J Clin Oncol
Year:: 2020
Journal volume:: 38 Suppl S
Journal issue:: 15
Print-ISSN:: 0732-183X
TUM Institution:: III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
BibTeX

Occurrences: